Journals / Fırat Tıp Dergisi / 2014 / Cilt: 19 - Sayı: 1

mRNA Expressions of NOS3 Gene among Patients with Multiple Sclerosis

Multiple Sklerozlu Hastalarda NOS3 Geninin mRNA Seviyesinde İfadesi

Pages
38–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that the mean age of patients with MS was 35.60 and in the control group was 33.80.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: It is considered that genetic factors may play a role in the development of MS, which is caused by demyelination and axonal damage in central nervous system.
📊
Key Findings & Data:It is known that, contrary to NOS1 ve 2, gene expression of NOS3 from NOS family does not show neurotoxic effect, but has a protective activism.
💡
Conclusion & Impact:It was found that the mean age of patients with MS was 35.60 and in the control group was 33.80.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: It is considered that genetic factors may play a role in the development of MS, which is caused by demyelination and axonal damage in central nervous system. Several studies, showing that NOS has a neuroprotective activism, have been conducted. It is known that, contrary to NOS1 ve 2, gene expression of NOS3 from NOS family does not show neurotoxic effect, but has a protective activism. Therefore, this study aimed to investigate the relationship of NOS3 gene expression levels with MS disease. Material and Method: 93 MS patients between the ages of 17-65 were examined in the study at Gaziantep University school of medicine, Sahinbey Research and Application Hospital Neurology Department. The control group consisted of 93 healthy volunteers. It was found that the mean age of patients with MS was 35.60 and in the control group was 33.80. The study was conducted with RT-PCR method. Results: The gene expression in alleles of NOS3*2, NOS3*3, and NOS3*4 in NOS3 patient/control groups were observed to decrease significantly, and the differences between groups with the Mann-Whitney method within 95% confidence interval (p <0.05) were analyzed. Conclusion: A result of the reduced gene expression of NO, it might be considered that its protective effects on neuronal cells may be inadequate. NO and NOS3 genes might be expected to be a promising approach at diagnosis and the development of new treatment strategies. However; gene expression level of NOS3 gene may seem statistically different between patients and controls, since it shows a lot of variability in each group, in order to be able to claim that it is associated with the formation of MS, studies with larger patient groups are needed. This is the first study designed for that purpose

Özet

Amaç: Merkezi sinir sisteminde demiyelinizasyon ve akson hasarı ile oluşan multiple sklerozun (MS) gelişiminde genetik etmenlerin de rol alabileceği düşünülmektedir. Nitrik Oksit Sentazın (NOS) nöron koruyucu etkinliği olduğunu gösteren çeşitli çalışmalar yapılmıştır. NOS ailesinden NOS3'ün (eNOS) NOS1 ve 2'nin aksine artan gen ifadesinin nörotoksik etki göstermediği, koruyucu özelliği olduğu bilinmektedir. Bu nedenle bu çalışmada NOS3 geninin ifade düzeyinin MS hastalığı ile ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Gaziantep Üniversitesi Tıp Fakültesi Şahinbey Araştırma ve Uygulama Hastanesi Nöroloji Polikliniği'nde takip edilen 17-65 yaşları arası 93 MS hastası çalışma kapsamına alındı. Kontrol grubunu 93 sağlıklı gönüllü oluşturdu. MS'li hasta grubunda yaş ortalaması 35.60 (en küçük:17, en büyük:65); kontrol grubunda ise 33.80 (en küçük:20, en büyük:73) olarak bulundu. Real Time PCR yöntemi ile çalışma yapıldı. Bulgular: NOS3 genindeki NOS3*2, NOS3*3 ve NOS3*4 allellerinde gen ifadesinin hasta/kontrol gruplarında anlamlı olarak düştüğü gözlemlenmiş ve gruplar arasındaki farklar Mann-Whitney yöntemi ile %95 güven aralığında (p<0.05) analiz edilmiştir. Sonuç: Nitrik oksitin (NO) azalan gen ifadesi neticesinde nöron hücrelerini koruyucu etkinliğinin yetersiz kalıyor olabileceği düşünülebilir. NO ve NOS3 geninin tanı ve yeni tedavi stratejileri geliştirmede umut verici bir yaklaşım olabileceği düşünülebilir. Ancak, NOS3 geninin ifade düzeyleri hasta ve kontroller arasında istatistiki olarak farklı görünse de, her bir grup içerisinde çok değişkenlik gösterdiği için MS oluşumu ile ilişkili olduğunu iddia edebilmek için daha geniş hasta gruplarında yapılan çalışmalara ihtiyaç olduğu anlaşılmaktadır. Bu çalışma bu amaçla tasarlanmış ilk çalışmadır

🔖

Cite This Article

BAYRAMA, A., İĞCİ, M., YİĞİTER, R., ELÇİ, M. A., CENGIZ, B., ÖZTUZCU, S., İĞCİ, Y. Z., ULAŞLI, M., BAYRAKTAR, R., BOZGEYİK, İ., ÇAKMAK, E. A., ARSLAN, A. (2014). mRNA Expressions of NOS3 Gene among Patients with Multiple Sclerosis. Fırat Tıp Dergisi, Cilt: 19 - Sayı: 1, 38–42. https://ajindex.com/articles/223057

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21
  2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Eng J Med 2000; 343: 938-52
  3. Confavreux C, Aimard G, Devic M. Course and prognosis of multipl sclerosis assessed by the computerized data processing of 349 patients. Brain 1980 and 1980; 103: 281-300
  4. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Parts I and II. Acta Neurol Scand Vols Scand 1975; 51: 110-57
  5. Ebers GC, Sadovnick AD. Epidemiology. Multiple sclerosis 1997: 5-28
  6. Altıntaş A, Kantarcı O, Siva A. Multiple sklerozda sitokinlerin rolü. Türk Nörol Derg 1995; 4: 167-71
  7. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 1121-31
  8. Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci 2004; 283-9
  9. Berner M, Beghetti M, Ricou B, Rauge JC, Pretne R, Friedli B. Relief of severe pulmonary hypertension after clousure of a large ventricular septal defect using low dose ınhaled nitric oxide synthase ındicating a neural role for nitric oxide. Nature 1990; 347: 768-70
  10. Moncada S, Higgs A. The L-Arginin Nitric Oxide Pathway. N Engl J Med 1993; 329: 2002-12
  11. Anggard E. Nitric oxide: mediator, murderer and medicine. The Lancet 1994; 343: 1199-206
  12. Berner M, Beghetti M, Ricou B, Rauge JC, Pretne R, Friedli B. Relief of severe pulmonary hypertension after clousure of a large ventricular septal defect using low dose ınhaled nitric oxide synthase ındicating a neural role for nitric oxide. Nature 1990; 347: 768-70
  13. Koh PO. Ferulic acid modulates nitric oxide synthase expression in focal cerebral ischemia. 2012; 273-8
  14. Defer GL, Barre J, Ledudal P, Tillement JP, Degos JD. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995; 35: 143-8
  15. Yılmaz, NÇ. Multipl Skleroz ve Otoimmünite. 2006, Sağlık Bakanlığı Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Uzmanlık Tezi, 91 sayfa, İstanbul (Doç. Dr. Hulya TİRELİ). Altıntaş A, Benbir G. Miyelinizasyon, Demiyelinizasyon Ve Remiyelinizasyon Mekanizmaları. Turk Nöroloji Dergisi 2005; 2
  16. Conzales GG, Avellana-Adalid V, Alli C, Baron Van Evercooren A. Myelination of the cent